Your browser is no longer supported. Please, upgrade your browser.
RAPT RAPT Therapeutics, Inc. daily Stock Chart
RAPT Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.63 Insider Own1.00% Shs Outstand22.90M Perf Week-29.96%
Market Cap450.67M Forward P/E- EPS next Y- Insider Trans- Shs Float20.60M Perf Month-
Income-37.10M PEG- EPS next Q- Inst Own62.00% Short Float0.00% Perf Quarter-
Sales- P/S- EPS this Y-24.20% Inst Trans- Short Ratio0.00 Perf Half Y-
Book/sh-142.11 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh2.70 P/C7.29 EPS next 5Y- ROE- 52W Range11.85 - 42.00 Perf YTD51.38%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.14% Beta-
Dividend %- Quick Ratio18.20 Sales past 5Y- Gross Margin- 52W Low66.08% ATR5.36
Employees62 Current Ratio18.20 Sales Q/Q- Oper. Margin- RSI (14)- Volatility26.17% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.43 Prev Close21.18
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume129.15K Price19.68
Recom- SMA207.82% SMA507.82% SMA2007.82% Volume58,109 Change-7.08%
Nov-11-19 10:56AM  Weekly CEO Buys Highlight -30.25%
Oct-30-19 08:49PM  RAPT Therapeutics Announces Pricing of Initial Public Offering Business Wire
Jul-30-19 03:25PM  Rapt Therapeutics IPO: What You Need To Know Benzinga
Jul-28-19 02:08PM  IPO Outlook For The Week: Cannabis, Cancer Therapy, Sushi And Holographic AR Benzinga
RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.